standings, doubts or disagreements, for the fact that it is a diagnose that depends on interpretation frequently based on subjective and subtle criteria [3] . Lesions of undetermined significance, which do not define the existence or absence of malignant lesions, have represented from 10% to 20% of the cytopathological diagnoses in materials obtained in preoperative FNA of thyroid. Because of such a non-conclusive situation, several patients are referred to total or partial surgical removal of the thyroid, which is the procedure particularly suitable for the occurrence of malignant nodules. However, during the histopathological evaluation of the excised piece, it has been observed that, in general, more than two thirds of the lesions initially being of undetermined significance are in fact considered as benign. For some time, several authors have suggested that the use of molecular markers, or biomarkers, represent one of the alternatives to reduce the number of false positives and false negatives in diagnosing nodular thyroid. Several research groups have tried, and others have been trying to raise the quality of diagnose of was obtained. The articles were classified according to the volume of information offered (Table 1) , following the criteria: Class A (Excellent): from 80% to 100%; Class B (Regular): from 50 to 70%; Class C (Weak): from 0 to 40%.
The results of the expression of the marker as well as of the histopathology presented in each investigation were inserted in a contingency table 2x2 and, from the table, the main quantities assessing the diagnose tests were obtained: sensibility; specificity; predictive positive value; predictive negative value and diagnose accuracy.
results
After reading and correlation to the defined criteria, 95 articles from different electronic database were included in this study. Most of the studies (76.8%) were related to classes B and C. Only three articles had the total of elements of systematization available. The studies included were produced by research groups from 23 different countries and taken from 43 different periodicals. Most of the articles (56.8%) were from these lesions by assessing the expression for a specific marker or for a panel of markers. Several investigations, however, have been tested in order to show the quality of one or several markers from tissue samples resulting from partial or total thyroidectomy, for the volume, quality and availability of the material are admittedly superior. However, the main dilemma lies on the preoperative phase, and all efforts must be made focusing on the available material as well as on the quantity and quality offered by the FNA. The quantity of markers submitted to analysis has been growing, having some of these markers been assessed in one single chance, but it has not been possible to obtain the expected results yet. Some other markers were and have been submitted to investigation, due to the fact that, through them, promising results have been foreseen, and new results have come up. This review of literature is a result of the perception of the need for a careful gathering of such investigations together with their results in order to acquire knowledge about the markers or combinations that have a higher number of evidences, as well as of those markers proper to use and methodologically feasible in material resulting from FNA.
Materials and Methods
This investigation is a systematic review with secondary data analysis of other investigations that have used samples of material obtained from preoperative FNA of thyroid -recovered from electronic database PUBMED, MEDLINE, SCOPUS and LILACS -, and also of the active search for the references of such articles, between 1994 and June, 2011 (Fig. 1) . The inclusion criteria defined were as follows: a) the language the article was published in: English, French, Italian, Spanish or Portuguese; b) the main or secondary objective of the article: to differentiate malignant and benign thyroid lesion from the assessment of the expression of the molecular marker in material resulting from FNA; c) the markers had been submitted to assessment during the preoperative phase; d) the results expressed directly or led to the number of true positives (TP), false positives (FP), true negatives (TF) and false negatives (FN), for each antibody or individual mutation, even when a panel of markers had been analysed; and e) the histopathology of excised piece had been considered as the gold standard of diagnose.
The articles were assessed and the data that composed a systematization form previously elaborated RET) and HBME-1(Hector Battifora Mesothelial Antigen-1). These markers were referred to and involved in 81% of the investigations included here.
Thirty (31.6%) out of the ninety-five articles selected included studies with panels of markers ( Table 2) and 65 (68.4%) used only one marker. In the studies with markers in panel during use, GAL3, BRAF, RET and HBME-1 have excelled, respectively. In the investigations that used only one marker, there was clear predominance of GAL3 and of the BRAF mutation.
The streptavidin-biotin-peroxidase complex was the predominant method in the immunocytochemical investigations (Table 3) The immunocytochemical studies composed predominantly their samples in the form of smears (56.6%), followed by a cell block (39.5%), immunoblotting (1.9%) and nonspecified (1.9%). Regarding mutations or gene expression, the samples consisted of liquid based preparations (38.6%), reprocessing smear for extraction of nucleic acid (31.8%) and wash out fluid (29.5%). discussion First, it seems important to consider that, although it has been acknowledged that some markers have better qualification, sensibility or specificity, for one or more histological subtypes, due to the genetic alterations in lesion [4] , either the differences of the main localization of the marker in cell or the morphological characteristics of the lesion [5] , the objective of this investigation was not to assess the qualification of the markers concerning one specific histological subtype, but to identify the information register considered to be relevant (elements of systematization) in experiments with molecular markers regarding preoperative FNA of thyroid, as well as how to consolidate values expressed by them through similar methodologies.
The challenges imposed during a review like this must be acknowledged, for the fact that different research protocols are applied to the same theme, leadItaly and the United States.
The articles included here have gathered 8,274 thyroid nodules that were submitted to preoperative FNA. The histological subtype of lesion has not been distinguished in eleven investigations, leaving 7,776 identified lesions classified as follows: among the benign lesions there were 2,019 adenomas, 842 goiters, 677 hyperplasias and 204 other lesions; among the malignant lesions there were 3,204 papillary carcinomas and variants, 699 follicular carcinomas, 52 medullary carcinomas and variants; 38 anaplastic carcinomas and 41 other malignant lesions. Among the other 84 investigations in which lesions were distinguished, it was observed that experiments have been carried out on several histological subtypes in 69 of such investigations, being them simultaneously malignant or benign. Regarding the size of the samples, there was a predominance of studies (35.8%) that used samples higher than 90 nodules (Fig. 2) . Most of the studies (69.4%) did not differentiate the gender of participants of the sample; 64.2% did not make reference to the participants' age and 57.4% did not indicate the approval of the investigation by any ethics committee or similar.
No reference was made to the dilution of the marker or to the final concentration in 44.5% of the studies, and other 13% followed the manufacturers' orientations. Only 29 (30.5%) studies indicated the participation of more than one cytopathologist in the assessment of results of the expression of the markers. Most of the studies (58.9%) did not make reference to the gauge of the needle used to puncture the nodules.
The articles selected refer to expression studies of 36 different markers in preoperative FNA of thyroid. The most highlighted ones were GAL3 (Galectin-3, a member of the beta-galactosidase binding protein family), BRAF (Proto-oncogene B-RAF), RET (Proto-oncogene marker, the GAL3, presented more than four criteria of assessment: strong; mild; weak or negative; nuclear and/or cytoplasmic immunostaining; < 50% versus > 50%; < 10%, from 11% to 49% and > 50%; < 10% versus > 10%; • What qualifies an investigation is the existence of more than one observer, who must intervene independently. About 60% of the studies do not indicate the number of cytopathologists involved in the assessment of results shown by the marker. It was observed a scarcity of studies (≤ 2 studies) on 26 markers (Tables 3 and 4) : CA19-9 (carbohydrate antigen 19-9) and CD15 [7] , CXCR4(CXC chemokine receptor 4) [8] , onfFN (onconfetal fibronectin) [9] , HMGI (High Mobility Group I) [10] , Ki67 and Laminin [11] , Lactoferrin [12] , MET(hepatocyte growth factor receptor) [13] , p63 [14] , S100/VDAC1(voltage dependent anion channel 1)/Galectin-1 [15] , PPARgamma (Peroxisome proliferator activated receptor gamma [16] , ing to variations of methodological quality, making it hard to compare previous investigations. Such methodological differences generate huge discrepancies of results among studies of several markers [6] .
Although this investigation did not intend to discuss operative characteristics of laboratory techniques to identify markers, the number of differences among techniques and methods used in the studies included must be highlighted. Differences from gauge needles used for puncturing, moving to the dilution or final concentration of the marker, up to the criteria of measurement of immunostaining are identified. Some examples are:
• It was observed that six out of the seven studies analysing CK-19 (Cytokeratin-19) in preoperative FNA of thyroid, have identified dilution, and all of them were different among themselves, varying from 1:40 to 1:400. This fact was reproduced in different markers; • Studies assessing the immunostaining of the same 2008 HBME-1**** TPO DAP IV Torregrossa et al. [8] 2010 HBME-1 GAL3 CXCR4 Franco et al.
2009 HBME-1 GAL3 Torres-Cabala et al. [15] 2006 GAL1 GAL3 S100C VDAC1 Saggiorato et al. [6] 2005 GAL3 HBME-1 TPO CK-19 KS Rossi et al.
2005 GAL3 HBME-1 RET Pineda et al. [27] 2003 GAL3 MUC-1 DAP IV Asioli et al. [21] 2010 GAL3 HBME-1 EMERIN Troncone et al. [17] 2009 CYCLIN D1 CYCLIND3 Pisani et al. [11] 2003 Ki67 LAMININ Aratake et al.
2002 GAL3 DAP IV Chandan et al. [23] 2006 CD-57 GLUT-1* Nar et al.
2011 CYCLIN A*** CYCLIN B1*** * There was no mutation in the samples selected. ** Only one mutation present in the sample. *** In FNA samples, the marker was negative for benign and malignant lesions. **** Postoperative FNA. to the proto-oncogene RAS, i.e., a huge number of malignant lesions histopathologically confirmed did not show the presence of this mutation. GAL3 is one of most frequently investigated molecular markers for the diagnose of the thyroid cancer [34] , be it in tissues [35] or in cytological material of FNA, as shown in this study. The studies published up to the present have not offered a definite answer for the use of GAL3 in clinical practice. Methodological matters are mentioned by several authors [36] [37] [38] [39] as being responsible for the controversial results published regarding GAL3.
Despite the fact that different and possible methodological flaws have been mentioned by several authors, GAL3 has shown in this study, by immunocytochemistry, an explicit uniformity of average value for the sensibility, specificity, positive predictive value, negative predictive value and diagnose accuracy, i.e., in all of them, GAL3 has obtained value equal or superior to 80%. The result represents much more for the continuity of research with the GAL3 with a standardization of procedures [37] than for an alleged ban of its use in FNA of thyroid [36] .
The BRAF mutation has presented extraordinary average values of specificity (97.9%) and positive predictive value (99.9%) resulting from the occurrence of only seven false positive results identified in three investigations [40] [41] [42] , among the 2800 malignant and benign lesions used in the 26 investigations including BRAF. The different methods used in the detection of marker do not seem to be a disadvantage, because of the fact that they present similar results [43] .
Finally, the BRAF mutation, for its unquestionable specificity, and the GAL3, for its regularity of average results obtained here, found in several locations in the cell as well as out of the cell, suggesting multiple functions of this molecule, were observed as holders of more expressive evidence in the effort of reducing the uncertainty of the diagnose in preoperative FNA of thyroid.
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Cyclin D3 and Cyclin D1 [17] , KS (Keratan-sulphate) [6] , FRA-1(Fos-related antigen 1) [18] , HMFG2 (human milk fat globule) and Tg (Thyroglobulin) [9] , Cyclin A and B1 [20] , Emerin [21] , CD57 (Human Natural Killer 1) [22, 23] , HMGA2 (High Mobility Group A2) [24, 25] and MUC-1 (mucin-1) [26, 27] , as well as a time difference (≥ 5 years) of the studies of 17 markers. The lack of continuity of research regarding the markers concerning material obtained from FNA of thyroid seems to be associated with certain factors, such as: a) Significant results obtained about cancer in different organs, but not presenting relevant results concerning cytological samples of thyroid; b) Samples used in the studies in relatively non-representative numbers, which make it impossible to come to any conclusion; c) Difficulties with the application and reproduction of methodology and techniques applied in the assessment of the expression of the marker, especially in studies of retrospective nature, while the preparation of the slide is an extremely important factor for the success of the study; d) The acknowledgement throughout the years of the fact that it is impossible to have one single marker to reduce the number of undetermined preoperative FNA. Among the most frequent studies (≥ 4 studies), some findings seem to be necessary for evidence regarding the performance of each marker, such as: a) The fact that the last record of studies about Telomerase and CD44 were obtained, respectively, in 2006 and in 2004; b) Among the eight studies that used TPO (Thyroperoxidase), six were carried out more than 5 years ago and, between the most recent two studies, one of them used the marker in panel together with HBME-1 and DAP IV (Dipeptidyl Aminopeptidase IV); c) Several authors [14, 28, 29] mentioned difficulties of interpretation concerning the distribution and intensity of expression of CK-19; d) Divergences of interpretation of HBME-1staining pattern are reported in several studies [20, [29] [30] [31] ]; e) RET/PTC is not expressed in follicular carcinoma [32] , and shows low prevalence in the follicular variant of the papillary carcinoma [33] ; f) Absence or insufficiency of follicular carcinoma cases in the studies that assessed the DAP IV; g) One of the lowest sensibility obtained was attributed
